Please login or sign up to post and edit reviews.
TWiV 853: COVID-19 clinical update #97 with Dr. Daniel Griffin
Media Type |
audio
Categories Via RSS |
Medicine
Science & Medicine
Publication Date |
Jan 15, 2022
Episode Duration |
00:53:39

In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis.

Subscribe (free): iTunesGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis. Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Quarantine and isolation (CDC) Outcomes before and after Omicron (medRxiv) Infectious viral load in Delta vs Omicron infections (medRxiv) PCR vs rapid antigen test (medRxiv) Booster interval to 5 months (FDA) Cross-reactive memory T cells (Nat Comm) Risk factors for severe outcomes in vaccinated (MMWR) Vaccine effectiveness vs MIS-C (MMWR) Cross-reactive T cells to Omicron from vaccines (medRxiv) Rivaroxiban for thromboprophylaxis (Lancet) Letters read on TWiV 853 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis.

Subscribe (free): iTunesGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review